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progression by enhancing AIB1 expression
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Abstract 
Background: General control non-depressible 5 (GCN5) is a crucial catalytic component of a transcriptional regu-
latory complex that plays important roles in cellular functions from cell cycle regulation to DNA damage repair. 
Although GCN5 has recently been implicated in certain oncogenic roles, its role in liver cancer progression remains 
vague.
Results: In this study, we report that GCN5 was overexpressed in 17 (54.8 %) of 31 human hepatocellular carcinoma 
(HCC) specimens. Down-regulation of GCN5 inhibited HCC cell proliferation and xenograft tumor formation. GCN5 
knockdown decreased the protein levels of the proliferation marker proliferating cell nuclear antigen (PCNA) and 
amplified in breast cancer 1 (AIB1), but increased the protein levels of cell cycle inhibitor p21Cip1/Waf1 in HepG2 cells. 
GCN5 regulated AIB1 expression, at least in part, by cooperating with E2F1 to enhance AIB1 transcription. Consist-
ently, GCN5 expression was positively correlated with AIB1 expression in human HCC specimens in two GEO profile 
datasets.
Conclusion: Since AIB1 plays a promoting role in HCC progression, our results propose that GCN5 promotes HCC 
progression at least partially by regulating AIB1 expression. This study implicates that GCN5 might be a potential 
molecular target for HCC diagnosis and treatment.
Keywords: Amplified in breast cancer 1 (AIB1), Cell proliferation, General control non-depressible 5 (GCN5), 
Hepatocellular carcinoma (HCC), Histone acetyl transferase (HAT)
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Background
Hepatocellular carcinoma (HCC) is the fifth most prev-
alent cancer and the second most common cause of 
cancer-related death worldwide [1]. Despite significant 
progression in diagnosis of HCC, the treatment still lacks 
clinical efficacy and remains unsatisfactory. Recurrence 
and metastasis are the main reasons for mortality after 
the clinical therapy [2], and the 5-year survival rate is 
limited to mere 30 % [3]. Thus, dissection of the underly-
ing mechanism of HCC progression and identification of 
potential molecular targets of HCC are crucial.
General control non-depressible 5 (GCN5), is the first 
identified transcription-related histone acetyl transferase 
(HAT), and a vital catalytic component of a transcrip-
tional regulatory complex. GCN5 plays an important role 
in cellular functions, from cell cycle regulation to DNA 
damage repair [4–6]. Besides normal cellular functions, 
GCN5 has also been implicated in certain oncogenic 
roles. c-Myc is often over-expressed in human cancers 
and is associated with aggressive tumorigenesis and poor 
prognosis [7]. GCN5 increases the stability of c-Myc pro-
tein by acetylating its K323 residue [8, 9]. GCN5 acetylates 
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and stabilizes the translocated E2A-PBX1 oncoprotein in 
acute lymphoblastic leukemia (ALL) to aberrantly activate 
HOX, contributing to the failure of cell differentiation 
[10, 11]. Moreover, GCN5 directly interacts with pygopus 
homolog 2 (pygo2), a component of Wnt/β-catenin path-
way to enhance the growth of breast cancer stem like cells 
[12]. It has been reported that GCN5 interacts with E2F1 
and acetylates H3K9 on its promoter region to facilitate 
the expression of Cyclin E and Cyclin D1 to promote lung 
cancer cell proliferation and tumor growth [13]. In breast 
cancer cells, GCN5 modulates microtubule acetylation 
mediated by HBXIP (hepatitis B X-interacting protein) 
oncoprotein and enhances cell migration [14]. Recently, 
histone acetyltransferase inhibitors are shown to block 
neuroblastoma cell growth by suppressing GCN5 expres-
sion [15], which highlights the impacts of GCN5 inhibi-
tors as potential drugs to treat cancer.
Taken together, these reports indicate a very funda-
mental role of GCN5 in several types of cancers. Hith-
erto no conclusive study has been reported that signifies 
the role of GCN5 in HCC. With such conspicuous role of 
GCN5 in cellular functions and putative links to cancer, 
we investigated the role of GCN5 in HCC progression. 
We found that GCN5 was highly expressed in human 
HCC tissues and HCC cell lines. Further scrutiny of the 
role of GCN5 in HCC revealed that GCN5 potentiated 
HCC progression by enhancing the expression of AIB1, 
an oncogene that plays a vital promoting role in HCC 
progression.
Results
GCN5 expression is frequently up‑regulated in human HCC 
tissues and cell lines
To evaluate the involvement of GCN5 in HCC, we exam-
ined the expression of GCN5 in a set of 31 human HCC 
specimens and four different human HCC cell lines by 
Western blot analysis. Our results showed that GCN5 
protein levels were significantly up-regulated in 17 
specimens (54.8 %), but down-regulated in 8 specimens 
(25.8  %), in total of 31 HCC specimens versus the sur-
rounding non-tumorous liver tissues (Fig.  1a). Intrigu-
ingly, some GCN5 band shifts were observed (Fig.  1a). 
In addition, we observed that the mRNA levels of GCN5 
were significantly increased in HCC specimens com-
pared with non-tumorous tissues (Fig. 1b).
Furthermore, we analyzed GCN5 expression in human 
HCC cell lines MHCC97H, Sk-Hep-1, HepG2 and 
Huh-7 and hepatocyte cell line L-O2. We observed a sig-
nificant increase in GCN5 expression in HCC cell lines 
when compared to hepatocyte cell line L-O2 (Fig.  1c). 
Hence the elevated expression of GCN5 in human HCC 
specimens and cell lines indicates that GCN5 may be an 
imperative candidate in HCC progression.
GCN5 knockdown reduces HCC cell proliferation 
and colony formation
To determine the role of GCN5 in cell proliferation, HCC 
cell lines HepG2 and Huh-7 cells as well as hepatocyte 
cell line LO2 were transiently transfected with pCMV-
Myc-GCN5 expression plasmids to overexpress GCN5. 
As shown in Fig. 2a, GCN5 overexpression significantly 
enhanced the cell proliferation rate of HepG2, Huh-7, 
and LO2. Furthermore, two stable GCN5-knockdown 
HepG2 cell lines were established to determine the 
effects of GCN5 knockdown on cell proliferation. Knock-
down of GCN5 significantly decreased the cell prolif-
eration (Fig.  2b), and colony formation (Fig.  2c). These 
results indicate that GCN5 could potentially promote 
HCC cell proliferation and colony formation.
GCN5 knockdown inhibits xenograft tumor formation
To investigate the role of GCN5 in HCC progression 
in  vivo, we assessed the effects of GCN5 knockdown on 
the growth of HCC xenograft tumors in nude mice. We 
subcutaneously injected 1 × 106 HepG2 control cells (shC-
trl), shGCN5-1 and shGCN5-2 cells in dorsal flanks of 
five nude mice, respectively. Five days after injection, the 
tumors were measured every 2 or 3 days for 4 weeks with a 
Vernier caliper. GCN5-knockdown tumors grew consider-
ably slower as compared to the control tumors (Fig. 3a). At 
the end of study day (30th) the mice were sacrificed and 
tumors were excised. The control tumors and shGCN5-
knockdown tumors were aligned for comparison. As 
shown in Fig.  3b, HepG2-shGCN5-1 and shGCN5-2 
tumors were much smaller in size as compared to HepG2 
control tumors. The tumor volume of GCN5-knockdown 
group (38 ± 10 mm3) was only 34.4 % of the control group 
(110 ± 30 mm3) (Fig. 3c). Consistently, the expression of 
proliferation marker proliferating cell nuclear antigen 
(PCNA) was significantly decreased in all representative 
GCN5-knockdown HepG2 tumors (Fig. 3d). These results 
suggest that GCN5 plays a key role in HCC tumor growth.
GCN5 knockdown inhibits cell cycle progression
Since GCN5 knockdown decreased cell proliferation in 
HCC cells and attenuated the formation of HCC xeno-
graft tumors in nude mice, we hypothesized that inhi-
bition of HCC proliferation by GCN5 knockdown is 
due to the cell cycle arrest. To confirm our hypothesis, 
we analyzed the cell cycle dynamics by flow cytometric 
analysis. Comparing to the control cells, the cell popula-
tion in G1 phase was significantly increased in GCN5-
knockdown cells, with a corresponding decrease in S and 
G2/M phases (Fig. 4a). These data suggest that GCN5 is 
required for the G1-to-S phase transition and its knock-
down inhibits the growth of GCN5-knockdown cells by 
impeding G1/S phase transition of the cell cycle.
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To understand the mechanism by which GCN5 knock-
down inhibits cell cycle progression, protein levels of 
several cell cycle-related genes were compared. In two 
GCN5-knockdown cell lines, while the protein levels 
of PCNA were significantly decreased as expected, the 
protein levels of cell cycle inhibitor p21Cip1/Waf1 were sig-
nificantly increased (Fig.  4b). It has been reported that 
inhibition of Akt signaling can lead to up-regulation of 
p21Cip1/Waf1 [16], and GCN5 can regulate the activation 
of Akt [17], we therefore detected the protein levels of 
phosphorylated Akt at Ser473. As shown in Fig. 4b, the 
expression of phosphorylated Akt at Ser473 was signifi-
cantly decreased in GCN5-knockdown cells, suggesting 
that up-regulation of p21Cip1/Waf1 is at least in part due 
to the down-regulation of phosphorylated Akt in GCN5-
knockdown cells. AIB1 has been implicated in several 
cancers [18, 19], and attenuation of AIB1 frequently 
inhibits the activation of Akt signaling by suppressing the 
expression of insulin receptor substrate (IRS)-1 and IRS-2 
[20–22]. We therefore wondered whether the expression 
of AIB1 is down-regulated in GCN5-knockdown cells. 
Our results showed that GCN5 knockdown significantly 
decreased the protein levels of AIB1 (Fig.  4b). Consist-
ently, GCN5 knockdown significantly decreased the 
mRNA levels of AIB1, but increased the mRNA levels of 
p21Cip1/Waf1 (Fig. 4c). These results imply that GCN5 pro-
motes cell cycle progression at least in part through up-
regulating AIB1 to inhibit p21Cip1/Waf1 expression.
To further determine whether GCN5 regulates cell 
proliferation through AIB1, we performed rescue experi-
ment for proliferation in GCN5-knockdown cells: GCN5-
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Fig. 1 GCN5 expression is frequently up-regulated in human HCC tissues and cell lines. a Western blot analysis of GCN5 protein expression in a set 
of 31 human HCC specimens and surrounding non-tumorous tissues. N non-tumorous tissue, T tumor tissue. Asterisk indicates GCN5 up-regulated 
HCC specimens. Hash indicates GCN5 down-regulated HCC specimens. β-actin was used as a loading control. b Relative mRNA levels of GCN5 were 
up-regulated in HCC specimens. GCN5 mRNA levels in 41 pairs of specimens (tumorous and surrounding non-tumorous liver tissues) were meas-
ured by real-time PCR. Relative quantification was achieved by normalization to GAPDH. *p < 0.05. c Protein expression of GCN5 was up-regulated in 
HCC cell lines (MHCC97H, SK-Hep-1, HepG2, and Huh-7) compared with hepatocyte cell line L-O2. All cell lines were cultured in DMEM. β-actin was 
used as a loading control
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constructs, and then cell proliferation was measured by 
MTT assay. The results showed that transfection of AIB1 
expression constructs could restore cell proliferation 
potential of GCN5-knockdown cells (Fig. 4d), suggesting 
that GCN5 promotes HCC cell proliferation at least 
moderately through regulating AIB1 expression. Western 
blot analysis of AIB1-restored cells showed a decrease in 



































































































































































Fig. 2 GCN5 knockdown reduces cell proliferation in HCC cell lines. a GCN5 overexpression enhanced cell proliferation in HepG2, Huh-7 and L-O2 
cells. Overexpression of GCN5 was confirmed by Western blot analysis. MTT assay was performed to determine cell proliferation rate. *p < 0.05, 
**p < 0.01. b Proliferation was reduced in stable GCN5-knockdown HepG2 cells, as measured by MTT assay. Down-regulation of GCN5 was con-
firmed by Western blot analysis. c Knockdown of GCN5 inhibited HCC cell colony formation. *p < 0.05, **p < 0.01
Page 5 of 11Majaz et al. Cell Biosci  (2016) 6:47 
substantiates our results and validates that GCN5 pro-
motes cell cycle progression through up-regulating AIB1 
to inhibit p21Cip1/Waf1 expression.
GCN5 regulates AIB1 expression by enhancing de novo 
transcription of the AIB1 gene
Since the mRNA levels of AIB1 were down-regulated in 
GCN5-knockdown HepG2 cells, we wondered whether 
GCN5 can regulate de novo transcription of the AIB1 
gene. We therefore examined the effect of GCN5 over-
expression on the AIB1 promoter activity by using 
AIB1 promoter reporter assay. Our results showed that 
GCN5 significantly enhanced the AIB1 promoter activ-
ity (Fig. 5a). Unlike a transcription factor, GCN5 protein 
does not contain a DNA binding domain. Rather than 
binding to DNA directly, GCN5 is recruited by transcrip-
tion factors to specific regions of DNA to regulate gene 
transcription [23]. Because GCN5 has been shown to be 
a crucial component of E2F-1-transactivating complexes 
for stimulating E2F-dependent transcription [24], and 
E2F1 can enhance the AIB1 promoter activity directly 
[25], we contemplated whether GCN5 is required for 
E2F1-mediated up-regulation of AIB1 promoter activity. 
As revealed in Fig.  5b, overexpression of E2F1 signifi-
cantly enhanced the AIB1 promoter activity as expected, 
but knockdown of GCN5 significantly decreased the 
AIB1 promoter activity induced by E2F1 transfection. 
These results suggest that GCN5 cooperates with E2F1 to 
enhance de novo transcription of the AIB1 gene.
Consistently, ChIP assay revealed that GCN5 was 
recruited to AIB1 promoter at E2F1 binding sites (Fig. 5c). 
Analysis of AIB1 promoter suggested that −250/+350 bp 
region contains two E2F1 binding sites (Fig. 5d). We per-
formed mutation analysis to determine the role of these 
E2F1 binding sites in E2F1/GCN5-mediated activation 
of AIB1 promoter. We mutated E2F1 binding sites-1 
and sites-2 on AIB1 promoter and measured AIB1 pro-
moter activity induced by GCN5, respectively (Fig.  5d). 
Mutation of E2F1 binding site-1 significantly decreased 
the AIB1 promoter activity induced by GCN5 (Fig.  5e), 
whereas mutation of E2F1 binding site-2 had no effect on 
AIB1 promoter activity induced by GCN5 (Fig. 5e). These 
results suggest that GCN5 is recruited to E2F1 binding 
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Fig. 3 GCN5 knockdown inhibits xenograft tumor formation. a Knockdown of GCN5 inhibited HCC cell tumorigenesis in vivo. 1 × 106 HepG2 
control cells, shGCN5-1 and shGCN5-2 cells were subcutaneously injected into dorsal flanks of nude mice, respectively. Five days after cell injection, 
tumor volume was measured every 2 or 3 days. n = 5, *p < 0.05, **p < 0.01. b GCN5-knockdown tumors showed a significant decrease in tumor 
volume compared with control tumors. An image of tumors is shown. c Tumor volume was significantly reduced in GCN5-knockdown tumors. d 
The expression of the PCNA was decreased in GCN5-knockdown tumors























































































































































































Fig. 4 GCN5 knockdown inhibits cell cycle progression. a Cell cycle analysis of stable GCN5-knockdown cells and control cells were performed by 
flow cytometry. A total of 4 × 105 cells were seeded into six-well plates, synchronized by serum starvation for 24 h and re-entered into the cell cycle 
by an exchange of 10 % FBS DMEM for 24 h. Cell were harvested and cell cycle status was measured by flow cytometry. **p < 0.01. b The protein 
levels of PCNA, p-Akt and AIB1 were decreased, but the protein levels of p21 were increased in GCN5-knockdown cells. c The mRNA levels of AIB1 
were decreased, but the mRNA levels of p21 were drastically increased in GCN5-knockdown cells. *p < 0.05, **p < 0.01. d Forced expression of 
AIB1 rescued the proliferation of GCN5-knockdown HepG2 cells. Each experiment was performed at least twice with similar results. All data are the 
means + sd. (n = 3) at each time point. *p < 0.05, **p < 0.01. e Forced expression of AIB1 in GCN5 knockdown cells decreased the protein level of 
p21
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Fig. 5 GCN5 regulates AIB1 expression by enhancing de novo transcription of the AIB1 gene. a GCN5 enhanced AIB1 promoter activity. 293T cells 
were transfected with AIB1 promoter reporters with or without PCMV-Myc-GCN5 expression plasmids. Renilla luciferase was transfected as internal 
control. Luciferase activities were measured and normalized to renilla luciferase value. All data are mean of independent experiments with three 
replicates per experiments. **p < 0.01. b Knockdown of GCN5 significantly decreased AIB1 promoter activity induced by E2F1 transfection. 293T 
cells were transfected with AIB1 promoter reporters with pGIPZ-shGCN5 plasmids and/or E2F1 expression plasmids. Luciferase activities were meas-
ured 48 h after transfection. **p < 0.01. c GCN5 was recruited to AIB1 promoter, as measured by ChIP assay. HepG2 cells were lysed for ChIP assays 
using control IgG and anti-GCN5 antibody for immunoprecipitation. d Two E2F1 binding sites were mutated in AIB1 promoter. e Mutation of E2F1 
binding site 1 (+154 ~ +164 bp) significantly decreased the AIB1 promoter activity induced by GCN5 transfection. Luciferase activities were assayed 
and normalized to Renilla luciferase activities. **p < 0.01. f E2F1 knockdown reduced GCN5 enrichment on AIB1 promoter. siE2F1 was used to knock 
down E2F1 in HepG2 cells. Cells were lysed for ChIP assays using control IgG and anti-GCN5 antibody for immunoprecipitation. *p < 0.05. g GCN5 
knockdown reduced H3K9 acetylation of E2F1 binding site on AIB1 promoter as measured by ChIP assay using anti-histone H3 (acetyl K9) antibody 
for immunoprecipitation. **p < 0.01
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explore whether E2F1 is essential for GCN5 recruitment 
on AIB1 promoter, we knocked down E2F1 using siRNA 
and then performed ChIP assay. As shown in Fig.  5f, 
down-regulation of E2F1 reduced GCN5 enrichment on 
AIB1 promoter, suggesting that GCN5 is recruited to 
AIB1 promoter through associating with E2F1.
To determine whether GCN5 is needed to acetylate 
H3K9 around E2F1 binding site 1 on AIB1 promoter, we 
knocked down GCN5 and performed ChIP assays using 
anti-histone H3(acetyl K9) antibody. Our results showed 
that H3K9 acetylation of E2F1 binding site 1 on AIB1 
promoter was significantly reduced in GCN5-knock-
down cells as compared to control cells (Fig. 5g), indicat-
ing that GCN5 regulates AIB1 expression by acetylating 
H3K9 around E2F1 binding site 1 on AIB1 promoter.
The expression of GCN5 positively correlates with AIB1 
in human HCC specimens from two GEO profile datasets
To determine whether the positive correlation between 
the expression of GCN5 and AIB1 can be verified in a 
larger cohort of human HCC specimens, we analyzed 
the expression of GCN5 and AIB1 in human HCC speci-
mens from two GEO profile datasets (GSE41619 and 
GSE62743). The expression of GCN5 was positively 
correlated with AIB1 in these two GEO profile datasets 
(Fig.  6). These results further support our notion that 
GCN5 regulates AIB1 expression.
Collectively, we draft a possible model in which GCN5 
enhances HCC proliferation at least partially by enhanc-
ing AIB1 expression: GCN5 associates with E2F1 and 
binds to AIB1 promoter to enhance AIB1 transcription 
by promoting the H3K9 acetylation on AIB1 promoter, 
which leads to hyper proliferation of HCC (Fig. 7).
Discussion
In this study, we demonstrated the key role of GCN5 in 
HCC progression. GCN5 was up-regulated (54.8  %) in 
human HCC specimens and in several HCC cell lines, 
suggesting the involvement of GCN5 in HCC progres-
sion. This notion is supported by the fact that GCN5 
knockdown hampered the in vitro proliferation of HCC 
cells and the in vivo growth of HCC tumors in nude mice.
Down-regulation of GCN5 in HepG2 cells resulted 
in cell cycle arrest. The expression of cell cycle inhibi-
tor p21Cip1/Waf1 was significantly increased in GCN5-
knockdown HepG2 cells, suggesting that up-regulation of 
p21Cip1/Waf1 at least in part accounts for cell cycle arrest. 
It has been reported that inhibition of Akt signaling 
can lead to the up-regulation of p21Cip1/Waf1 [16]. In this 
study, we demonstrated that GCN5 knockdown signifi-
cantly inhibited Akt signaling by down-regulating p-Akt 
expression, indicating that up-regulation of p21Cip1/Waf1 
in GCN5-knockdown HepG2 cells is partly due to the 
reduced Akt signaling. Our previous study has shown 
that AIB1 is a bonafide oncogene that is overexpressed in 
human HCC specimens and promotes HCC progression 
by enhancing cell proliferation and invasion, and AIB1 
knockdown leads to p-Akt down regulation, p21Cip1/Waf1 
up-regulation and cell cycle arrest in HepG2 cells [26]. 
Therefore, we speculated that GCN5 knockdown inhibits 
HCC cell proliferation by down-regulating AIB1 expres-
sion. Indeed, knockdown of GCN5 markedly decreased 
both protein and mRNA levels of AIB1, suggesting that 
GCN5 promote HCC cell proliferation at least in part by 
enhancing AIB1 expression.
In this study, we demonstrate that GCN5 can cooperate 














































Fig. 6 The expression of GCN5 positively correlates with AIB1 in human HCC specimens from two GEO profile datasets. a Positive correlation 
between GCN5 and AIB1 (R = 0.51, p < 0.01, n = 88). Expression profiles of 88 human HCC specimens from a GEO dataset (GSE43619). The GCN5 
probe ID used was ILMN_1782247, the AIB1 probe ID used was ILMN_1708805. b Positive correlation between GCN5 and AIB1 (R = 0.4, p < 0.01, 
n = 132). Expression profiles of 135 human HCC specimens from a GEO dataset (GSE62743). The GCN5 probe ID used was ILMN_1782247, the AIB1 
probe ID used was ILMN_1708805
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has been shown that AIB1 can also cooperate with E2F1 
to enhance gene transcription [25], and E2F1 can stimu-
late GCN5 transcription [27]. Therefore, it is possible 
that AIB1 can cooperate with E2F1 to enhance GCN5 
transcription. If so, GCN5 and AIB1 may form an ampli-
fication circuit to up-regulate each other through cooper-
ating with E2F1, leading to dramatically enhanced cancer 
cell cycle progression. Further study is needed to validate 
this possibility.
GCN5 is a histone acetyl transferase (HAT), which 
acetylates histones to establish an active chromatin envi-
ronment for transcriptional activation. Inhibition of HAT 
enzymatic activity by using HAT inhibitors can result in 
the inhibition of cancer cell proliferation [15]. Several 
GCN5-specific HAT inhibitors such as CPTH2 have 
been developed [28, 29]. The effects of GCN5-specific 
HAT inhibitors on AIB1 expression and HCC cell prolif-
eration are under investigation.
Conclusions
Since AIB1 plays a promoting role in HCC progression, 
our results suggest that GCN5 promotes HCC progres-
sion at least in part by enhancing AIB1 expression. To 
our knowledge, this study emphasizes for the first time 
an important role of GCN5 in HCC progression. Our 
study leads us toward an additional strategy for targeting 
AIB1 in several cancers which could provide with new 
options for combinatorial therapies thus highlighting its 
significance as a potential therapeutic target for HCC 
treatment.
Methods
Tissue samples and cell lines
Tumorous and adjacent non-tumorous liver tis-
sues were collected from 31 patients who underwent 
surgery for HCC at the First Affiliated Hospital of Xia-
men University. Both tumor and non-tumorous tissues 
were confirmed histologically. Informed consent was 
obtained from each patient and the study protocol that 
conforms to the ethical guidelines of the 1975 Declara-
tion of Helsinki was approved by the Institute Research 
Ethics Committee, Xiamen University. Human HCC 
cell lines MHCC97H, SK-Hep-1, HepG2, and Huh-7 
and hepatocyte cell line L-O2 were cultured in DMEM 
supplemented with fetal bovine serum (FBS) and 
penicillin–streptomycin.
Cell transfection and luciferase activity assays
The HEK293T cells were transfected with reporter plas-
mids together with PCR3.1–Rluc as an internal control, 
in the presence of indicated plasmids by using CaCl2 
transfection. Cells were harvested 24  h post-transfec-
tion and luciferase activity was assayed and normalized 
to Renilla luciferase activity by using a dual luciferase 
reporter assay system (Promega, Madison, WI, USA).
RNA interference and stable cell lines
pGIPZ-shGCN5 plasmids were purchased from Thermo 
Scientific Company. To generate stably transfected cells, 
HepG2 cells were transfected with pGIPZ-shGCN5 
and control vector, respectively, Approximately 1  week 
after transfection the cells were treated with 1  μg/
ml puromycin for 3  weeks. Five hundred cells were 
placed in a 100  mm dish and individual drug resist-
ant clones were picked and expanded for further iden-
tification. The clones exhibiting significant GCN5 
knockdown were used for further experiments. GCN5 
specific targeting sequence is TTGAGGGTTGTG-
TAGAGCT and E2F1 specific targeting sequence is 
AAGUCACGCUAUGAGACCUCA.
TSS
0 +154 +164  +189 +199 
AIB1 promoter  







E2F1 binding sites 
Fig. 7 A proposed model illustrating the mechanism by which GCN5 enhances AIB1 expression and promotes proliferation of HCC cells. GCN5 
associates with E2F1 and binds to AIB1 promoter to enhance AIB1 transcription by acetylating H3K9 around E2F1 binding site 1 on AIB1 promoter
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Cell proliferation
Cell proliferation was analyzed by MTT assay. A total of 
3 ×  103 cells were seeded into 96-well plates and MTT 
was added to each well every 24 h. The plates were incu-
bated for 4  h before addition of solubilizing solution 
(0.01 M HCl in 10 % SDS). The absorbance was measured 
at 560 nm by using a microplate reader.
Cell cycle analysis
For cell cycle analysis, 4 ×  105 cells were synchronized 
by serum starvation for 24 h and induced to re-enter the 
cell cycle by an exchange of 10 % FBS DMEM for 24 h. 
Both floating and adherent cells were harvested and fixed 
in 75 % ethanol at 4  °C overnight. Cells were incubated 
with RNase A at 37  °C for 30 min, and then stained with 
propidium iodide (PI). Cell cycle was measured by flow 
cytometry.
Reverse transcription and real‑time PCR
Total RNA was isolated with Trizol reagent (Invitro-
gen) according to the manufacturer’s instructions. The 
cDNA was synthesized from 2  μg of total RNA using 
MMLV transcriptase (Toyobo, Shanghai, China) with 
random primers. Real-time PCR were performed using 
SYBR Premix ExTaq (TaKaRa, Dalian, China). Rela-
tive quantification was achieved by normalization to 
the amount of GAPDH. Primers used were: AIB1 for-
ward: GACCGCTTTTACTTCAGGCATT; AIB1 
reverse: TGTGTTAACCAGGTCCTCTTGCT; p21 
forward: CAGGGGAGCAGGCTGAAG; p21 reverse: 
GGATTAGGGCTTCCTCTTGG; GAPDH forward: 
AACTTTGGCATTGTGGAAGG, GAPDH reverse: 
GGATGCAGGGATGATGATGTTCT; GCN5 for-
ward: GCACAAGACTCTGGCCTTGA; GCN5 reverse: 




Equal amounts of protein lysates were separated by SDS-
PAGE and transferred onto PVDF membranes. Filters 
were probed with the following specific primary antibod-
ies: anti-GCN5 (Santa-cruz), anti-AIB1 (BD Bioscience) 
anti-p21Cip1/Waf1 (BD Biosciences), PCNA (Abcam, Cam-
bridge, MA, USA), β-actin (Sigma, St Louis, MO, USA), 
Akt and phosphorylated-Akt (Cell signaling, Danvers, 
MA, USA), Anti-histone H3 (acetyl K9) antibody-ChIP 
Grade (Abcam, Cambridge, MA, USA) anti-CyclinD1 
(Abcam, Cambridge, MA, USA). Blots were then incu-
bated with horseradish peroxidase-conjugated second-
ary antibody (Pierce, Rockford, IL, USA) and visualized 
by chemiluminescence. The band density was quantified 
by densitometry using Scion Image software and normal-
ized to β-actin levels.
Colony formation assays
For focus formation assay, 250 cells were cultured in six-
well plates in DMEM with 10 % FBS. After 3 weeks, cells 
were stained with 0.005 % crystal violet for 1 h to detect 
foci. Colonies >100 μm in diameter were counted.
ChIP assay
ChIP assay were processed according to the manufac-
turer’s instructions. The following primers were used 
to amplify the DNA fragment corresponding to the 




Four to 6-week-old male nude mice were obtained 
from Laboratory Animal Center of Xiamen Univer-
sity. 1  ×  106 HepG2-shGCN5 cells and control cells 
were subcutaneously injected into the dorsal flanks of 
mice, respectively. From day 5 after cell injection, the 
size of the tumor was measured every 2 or 3  days by a 
vernier caliper along two perpendicular axes. The vol-
ume of the tumor was calculated following the formula: 
Volume  =  Length  ×  Width2  ×  0.52. Thirty days after 
injection, mice were sacrificed and the tumors were pho-
tographed and used for western blot analysis. All experi-
mental procedures involving animals were performed in 
accordance with animal protocols approved by Labora-
tory Animal Center of Xiamen University.
Statistical analysis
The data were collected from several independent experi-
ments, with three replicates per experiment. All data 
were expressed as means  +  sd. Statistical significant 
effects (p value <0.05) were examined using t test in SPSS 
11.0 for Windows (SPSS Inc., Chicago, IL, USA).
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